Peptide · Antagonist · developed by Organon Usa Organon
Ganirelix is a synthetic peptide given by subcutaneous injection during controlled ovarian stimulation, used in the context of fertility treatment.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT00703014 | N/A | Pregnancy | Completed | OGN |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
NeonatesPregnancy
Updated Oct 25, 2026. Something wrong or missing? Report it on the OGN page.
See OGN's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
OGN catalysts and pipeline →